Sulfabenzamide

Summary

Sulfabenzamide (CHEMBL1243) is an approved small-molecule antibacterial drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 276.31 Da · C13H12N2O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1243
Name	Sulfabenzamide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5319
ChEBI	CHEBI:94677
Molecular formula	C13H12N2O3S
Molecular weight	276.31
InChIKey	PBCZLFBEBARBBI-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: N-(4-aminophenyl)sulfonylbenzamide

ChEBI definition: A sulfonamide containing a benzamido substituent on nitrogen. An antibacterial/antimicrobial, it is often used in conjunction with sulfathiazole and sulfacetamide as a topical, intravaginal antibacterial preparation.

Pharmacological roles (ChEBI): antibacterial drug, antimicrobial drug.

Also known as: NSC-74587, SID11112278, SID26746972, SID855720, SID144203961, SID170465133

Patent coverage: 996 distinct patent families (3,612 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, Menin/Histone-lysine N-methyltransferase MLL.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.2	Potency	6310	nM	CHEMBL_ACT_3654368

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).